The effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta 1 and migration-inhibitory factor levels in elderly patients with ovarian cancer

Abstract

Objective To investigate the effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta1 (TGF-β1) and macrophage migration-inhibitory factor (MIF) levels in elderly patients with ovarian cancer. Methods A hundred elderly patients diagnosed with ovarian cancer from December 2011 to December 2014 at our hospital were recruited.Participants were assigned into a joint therapy group (n=50) and a thermal therapy group (n=50) according to the received treatment.Both groups were given the abdominal hyperthermia chemotherapy treatment, while the joint therapy group was additionally given Bevacizumab treatment.The effectiveness of treatment, adverse reactions, pre-and post-treatment serum TGF-β1 and MIF levels, and the 2-year survival situation in all participants were collected and analyzed. Results The therapeutic response rate and 2-year survival rate in the joint therapy group (64.0% and 60.0%) were significantly higher than those in the thermal therapy group (44.0% and 40.0%) (both P 0.05). Conclusions Abdominal Bevacizumab combined with hyperthermia chemotherapy can effectively decrease the levels of serum TGF-β1 and MIF in elderly patients with ovarian cancer and achieve improved short-term and long-term effectiveness with good safety. Key words: Ovarian cancer; Transforming growth factor beta1; Macrophage migration-inhibitory factors; Bevacizumab; Hyperthermia chemotherapy